Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.39 |
| ▸ | AXL | P30530 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8114323 | 0.81 | HTR3E (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL14407094 | 0.77 | KMT2A (0.47) | ALDH1A1MEN1MAPTKMT2AGFER | |
| SCHEMBL83318 | 0.77 | CA12 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29352597 | 0.77 | CA12 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL14986662 | 0.76 | CA12 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL14407073 | 0.76 | KMT2A (0.39) | ALDH1A1MEN1MAPTKMT2AGAA | |
| SCHEMBL14407090 | 0.76 | TEAD4 (0.48) | ACHEALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL14407092 | 0.76 | KMT2A (0.39) | ALDH1A1MEN1MAPTKMT2AGFER | |
| SCHEMBL29096230 | 0.75 | CA12 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL15936174 | 0.74 | CA12 (0.43) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827657-B2 | Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof | Boehringer Ingelheim Animal Health USA Inc. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20220194965-A1 | BORON CONTAINING PYRAZOLE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF | BORAH, INC. | 2022-06-23 | — | — | US | disclosed |
| EP-2305651-A1 | 2,3,6-trisubstituted-4-pyrimidone derivatives | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-04-06 | — | — | EP | disclosed |
| US-20100159596-A1 | SMALL MOLECULE COMPOUNDS FOR STEM CELL DIFFERENTIATION | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827657-B2 | Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof | JAK3, JAK1, JAK2 | CA12 2075/4885CA1 2675/4885CA2 1365/4885 |
| US-20220194965-A1 | BORON CONTAINING PYRAZOLE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF | JAK3, JAK1, JAK2 | CA12 2075/4885CA1 2675/4885CA2 1365/4885 |
| US-20100159596-A1 | SMALL MOLECULE COMPOUNDS FOR STEM CELL DIFFERENTIATION | RCOR3, BRD3, BRPF3 | CA12 1978/4885CA1 1179/4885CA2 1775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.